New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis

Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nadwi, Huda, Janaini, Murad, Zammo, Mohammed, Cheikh, Mohamed, Almoallim, Hani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415454/
https://www.ncbi.nlm.nih.gov/pubmed/32801946
http://dx.doi.org/10.2147/IMCRJ.S265812
_version_ 1783569179050246144
author Nadwi, Huda
Janaini, Murad
Zammo, Mohammed
Cheikh, Mohamed
Almoallim, Hani
author_facet Nadwi, Huda
Janaini, Murad
Zammo, Mohammed
Cheikh, Mohamed
Almoallim, Hani
author_sort Nadwi, Huda
collection PubMed
description Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab?
format Online
Article
Text
id pubmed-7415454
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-74154542020-08-14 New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis Nadwi, Huda Janaini, Murad Zammo, Mohammed Cheikh, Mohamed Almoallim, Hani Int Med Case Rep J Case Report Secukinumab, “an IL-17 antagonist”, is one of the biological agents used to treat active ankylosing spondylitis (AS). Although it has been proven that certain agents are linked with a paradoxical increase in uveitis, there are limited data on whether secukinumab has this effect or not. We report a case of a new-onset anterior uveitis after 6 months of starting secukinumab in a 47-year-old male, HLA-B27 positive AS patient. He had a long-standing history with the disease over 25 years. He was treated in the past with methotrexate then adalimumab and later on with etanercept. He had no history of uveitis during all of this time. The uveitis was mild and treated conventionally with local measures while secukinumab was maintained. After a close follow-up, the uveitis had completely resolved. Is this part of the original disease or a possible side effect from secukinumab? Dove 2020-08-05 /pmc/articles/PMC7415454/ /pubmed/32801946 http://dx.doi.org/10.2147/IMCRJ.S265812 Text en © 2020 Nadwi et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Nadwi, Huda
Janaini, Murad
Zammo, Mohammed
Cheikh, Mohamed
Almoallim, Hani
New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title_full New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title_fullStr New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title_full_unstemmed New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title_short New-Onset Uveitis Possibly Caused by Secukinumab in a 47-Year-Old Male Patient with Long-Standing Ankylosing Spondylitis
title_sort new-onset uveitis possibly caused by secukinumab in a 47-year-old male patient with long-standing ankylosing spondylitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7415454/
https://www.ncbi.nlm.nih.gov/pubmed/32801946
http://dx.doi.org/10.2147/IMCRJ.S265812
work_keys_str_mv AT nadwihuda newonsetuveitispossiblycausedbysecukinumabina47yearoldmalepatientwithlongstandingankylosingspondylitis
AT janainimurad newonsetuveitispossiblycausedbysecukinumabina47yearoldmalepatientwithlongstandingankylosingspondylitis
AT zammomohammed newonsetuveitispossiblycausedbysecukinumabina47yearoldmalepatientwithlongstandingankylosingspondylitis
AT cheikhmohamed newonsetuveitispossiblycausedbysecukinumabina47yearoldmalepatientwithlongstandingankylosingspondylitis
AT almoallimhani newonsetuveitispossiblycausedbysecukinumabina47yearoldmalepatientwithlongstandingankylosingspondylitis

Ejemplares similares